Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort

When present during the course of chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH) is usually of moderate severity: the mean pulmonary artery pressure (mPAP) at rest ranges from 25 to 35 mmHg, with preserved cardiac output [1, 2]. However, a subset of COPD patients presents a particular vascular phenotype called severe PH, characterised by a much higher mPAP or a low cardiac index [1–8]. According to the latest world symposium on PH, severe PH-COPD is defined as mPAP>35 mmHg or mPAP>25 mmHg with low cardiac index (<2 L min m−2) [1, 2]. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: Dr. Dauriat has nothing to disclose. Conflict of interest: Dr. Reynaud gaubert has nothing to disclose. Conflict of interest: Dr. Cottin reports personal fees and non-financial support from Actelion, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees from Bayer / MSD, personal fees from Novartis, personal fees and non-financial support from Roche / Promedior, personal fees from Sanofi, personal fees from Celgene, personal fees from Galapagos, personal fees from Galecto, personal fees from Shionogi, personal fees from Astra Zeneca, personal fees from Fibrogen, outside the submitted work;. Conflict of interest: Dr. Lamia has nothing to disclose. Conflict of interest: Dr. Montani has nothing to disclose. Conflict of interest: Dr. Belhadi has nothing to disclose. Conflict of interest: Dr. Humbert reports personal fees from Acceleron, grants and personal fees from Actelion, grants and personal fees from Bayer Heathcare, personal fees from GSK, personal fees from Merck, personal fees from Novartis, personal fees from Astrazeneca, personal fees from Sanofi, outside the submitted work. Conflict of interest: Dr. Laouenan has nothing to disclose. Conflict of interest: Dr. Mal reports personal fees from Boeringher, personal fees from Novartis, non-financial support from Pulmonx, outside the submitted work;.